The US Food and Drug Administration (FDA) has approved cabozantinib (Cabometyx, Exelixis, Inc.) for certain adults and children aged ≥ 12 years with previously treated, well-differentiated pancreatic ...

A neuroendocrine tumor (NET) is a slow-growing type of cancer that begins in your hormone-producing cells. It is rare, but doctors diagnose more cases each year. An estimated 170,000 Americans ...

Cabozantinib improves progression-free survival (PFS) in patients with advanced extrapancreatic neuroendocrine tumors and pancreatic neuroendocrine tumors compared with placebo. Cabozantinib, an oral ...

Neuroendocrine cancer, a rare disease affecting hormone-making cells, tragically claimed the life of actor Irrfan Khan in ...

As a national leader in diagnosing and treating NETs, we have helped hundreds of patients get the answers they seek and the treatment they need. We offer diagnostic therapies and the latest, most ...

Please provide your email address to receive an email when new articles are posted on . Researchers reported reductions in risk for disease progression or death with cabozantinib vs. placebo for both ...

Addressing the "Apple Community" in a statement, Jobs said his doctors think they have found the reason behind his weight loss: "a hormone imbalance that has been 'robbing' me of ...

Pancreatic cancer remains one of the most challenging cancers to detect early, contributing to its reputation as a silent disease with poor survival rates. The pancreas—a leaf-shaped organ tucked ...